Events

First IATDMCT Regional Meeting in China
Better TDMCT, Better Treatment
September 24-25, 2010, Beijing China (More info)


12th International Congress of TDM & Clinical Toxicology
October 2 - 6, 2011
Stuttgart Germany
2011 meeting

 

 

 

Login

Forgot Password

Our aims are:

  • To promote the knowledge and understanding of clinical drug analysis and interpretation of results.

 

  • To enhance communication between scientists and physicians of all disciplines involved in therapeutic drug monitoring and clinical toxicology.

 

  • To encourage the effective application of therapeutic drug monitoring and clinical toxicology; with the aim of optimizing clinical drug use and maximizing the clinical and economic benefits.

 

Application form (PDF) (Word)

 

Journal

IATDMCT is assuming ownership of Therapeutic Drug Monitoring journal

IATDMCT members have free on-line access to the journal Therapeutic Drug Monitoring.

Instructions for authors

Council Members

President
Dr. Alexander Vinks

Alexander (Sander) Vinks is Professor of Pediatrics and Pharmacology (Adj.) at the University of Cincinnati, Colleges of Medicine and Pharmacy. He is the director of the Division of Clinical Pharmacology, principal investigator of the NIH Pediatric Pharmacology Research Unit at Cincinnati Children’s and Director of the Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management. Dr. Vinks received his pharmacy and pharmacology training at Leiden University and the University of Toronto, Canada. He received specialty training in clinical pharmacy (PharmD) and clinical pharmacology (PhD) at The Hague Hospitals Central Pharmacy and Leiden University in the Netherlands. Dr. Vinks is board certified in Clinical Pharmacology and Toxicology. Before joining the Division of Clinical Pharmacology at Cincinnati Children’s in 2000, he was Director of the centralized Clinical Pharmacology & Toxicology Laboratory for the city of The Hague. His major research interests include pharmacokinetic-pharmacodynamic (PK/PD) modeling, pharmacogenetics (PG) and the application of genomic, population and simulation approaches (Pharmacometrics) to clinical trial design, Therapeutic Drug Monitoring (TDM) and individualized Bayesian dosing strategies. His current research includes the development of biomarker assays for the measurement of pharmacodynamic effects of immunosuppressive drugs. Dr. Vinks has ongoing NIH funding to further advance PK/PD/PG modeling and simulation in pediatric patients with a focus in optimizing immunosuppressive and antimicrobial therapies. He is directing several clinical pharmacology cores for ongoing multi-center clinical studies evaluating target controlled therapies using population model-based approaches. Dr. Vinks has received several distinctions for his research, including the Huizinga Award for Research in Hospital Pharmacy from the Netherlands. Dr. Vinks is president-elect of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He is chairing the Therapeutic Monitoring and Toxicology (THE) scientific section of the American Society of Clinical Pharmacology and Therapeutics (ASCPT) and is a fellow of the American College of Clinical Pharmacology. He is on the Editorial Board of Antimicrobial Agents and Chemotherapy, Clinical Therapeutics, Therapeutic Drug Monitoring, Journal of Pediatric Pharmacology and Therapeutics, and the Journal of Clinical Medicine (Bulgaria). Dr. Vinks is an internationally renowned speaker with more than 140 presentations at national and international meetings. He has authored over 70 peer-reviewed publications and 14 book chapters and reviews in the areas of PK/PD modeling, pharmacogenetics and TDM.

Dr. Alexander A. Vinks
Professor of Pediatrics
Cincinnati Children’s Hospital and Medical Center
MLC 6018, Oak South Room 2529
3333 Burnet Avenuen
Cincinnati OG 45229-3039
USA
Sander.vinks@chmcc.org
 
President-Elect

Prof. Pierre Marquet

 Pierre Marquet has been a Doctor of Medicine since 1986 and obtained a master in statistics and epidemiology followed by a PhD in physiology in 1992. After several years as a toxicologist at Limoges University Hospital, he has been an associate professor of pharmacology since 1998 and in 2001, became a full professor at the Faculty of Medicine of Limoges, France. He is head of the “Clinical PK and TDM” unit and of “Clinical research in TDM and toxicology” at the University Hospital of Limoges. He is also the Director of the INSERM U850 research unit called “Pharmacology of immunosuppressive drugs in transplantation” (INSERM is the French Institute of Medical and Health Research).

He conducts translational research on treatment personalization, mainly concerning immunosuppressants (IS) in organ transplantation, which covers: new analytical methodologies for IS; metabolic and pharmacogenetic studies of the IS; application to population pharmacogenetic-pharmacokinetic analysis and therapeutic drug monitoring; and epidemiological studies and clinical trials in transplant patients.

He has published over 120 papers in peer-reviewed, international journals.

Dr. Pierre Marquet
Pharmacology & Toxicology
University Hospital
2 av Martin Luther King
Limoges Cedex 87042
France
Pierre.marquet@unilim.fr

Past President
Prof. Dr.Dr. h.c. Hans H. Maurer
 Hans H. Maurer is full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, University of Saarland, since 1992. He is head of the Department of Experimental and Clinical Toxicology. His main two areas of research are analytical toxicology (GC-MS, LC-MS of drugs, poisons and their metabolites) and in-vitro and in-vivo metabolism (phase I and phase II, isoenzyme identification, pharmacogenetics). He has published extensively in both areas (besides original papers, reviews and proceedings, handbooks and computer databanks on GC-MS).

He is editorial board member of the Journal of Chromatography B, Therapeutic Drug Monitoring, Analytical and Bioanalytical Chemistry, Current Pharmaceutical Analysis, Current Drug Metabolism, Drug Metabolism Letters, Annales Pharmaceutiques Françaises, SUCHT - German Journal of Addiction Research and Practice, and reviewer of most of the international journals of his field as well as of scientific research foundations in Germany, UK, Switzerland, and New Zealand. He was guest editor of special issues of Journal of Chromatography B (1998), Therapeutic Drug Monitoring (2002 and 2004) and Analytical and Bioanalytical Chemistry (2007).

In his career, Dr. Maurer received several scientific awards, among which the Young Investigator Award of the Medical Faculty presented in Homburg 1983, the Irving Sunshine Award for Outstanding Contributions to Clinical Toxicology of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDM-CT) presented in Vancouver 1997, "Membre d'Honneur" de la Société Française de Toxicologie Analytique (SFTA) presented in Dinard 2003, and finally the Alan Curry Lifetime Achievement Award of TIAFT for Outstanding Contributions to Forensic Toxicology presented in Melbourne 2003. In 2007, he received the Doctor honoris causa degree of the University of Ghent in Belgium for his outstanding scientific achievements.

Besides his membership in several national and international scientific societies, Dr. Maurer is President of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDM-CT, 2007-2009) and is TIAFT executive board member (2005-2011), treasurer of the Society of Toxicological and Forensic Chemistry (GTFCh, since 1987), chairman of the GTFCh Committee "Clinical Toxicology", since 1997, and finally chapter president of Saarland of the German Pharmaceutical Society (DPhG, 2004-2006).

Professor Dr. Dr. h.c. Hans H. Maurer
Head, Department of Experimental and Clinical Toxicology
Institute of Experimental and Clinical Pharmacology and Toxicology
Saarland University, D-66421 Homburg/Saar (Germany)
e-mail: hans.maurer@uks.eu
web: http://wwwalt.med-rz.uniklinik-saarland.de/med_fak/pharma-toxi/Seiten/Maurer_frame.html

Secretary
Dr. Donald LeGatt
 Dr. LeGatt is a Clinical Biochemist who has been head of the Clinical Toxicology and Therapeutic Drug Monitoring Laboratory at University of Alberta Hospital, Edmonton for twenty eight years. He is a Clinical Professor at the University of Alberta with teaching responsibilities in the Faculty of Medicine and Dentistry and has been a Consultant Toxicologist at DynaLIFE, Edmonton for eleven and a half years. His actual “roots” are in Pharmacy, having obtained both his Bachelor’s and Ph.D degrees in the discipline. He has been a Member of IATDMCT since 1990, and has previously served as a Councilor and Director of Education. He has also served on the organizing Committees of three Congresses. Dr. LeGatt is a Founding Fellow of the Canadian Academy of Clinical Biochemistry (CACB), and has been a member of the Canadian Society of Clinical Chemists (CSCC) and the American Association of Clinical Chemistry (AACC) since 1983. He has also served three terms as President of  the Alberta Society for Human Toxicology (ASHT). He has received several awards:  a Capital Health “Esprit de Corps” Recognition Award in 1997; a CSCC International Visitor Award in 2001; in 2005, the Certificate for Meritorius Service from the College of Physicians and Surgeons of Alberta, the CSCC Education Excellence Award and a Capital Health Reach Award for Innovation Excellence; in 2006, an “Outstanding Speaker Award” from AACC; in 2008, a City of Spruce Grove Award of Excellence for Innovation and a CSCC Best Poster Award; in 2009,  the “Teacher of the Year Award” in Clinical Pathology, University of Alberta. He is an avid proponent of progressive, rational clinical toxicology testing. Dr. LeGatt’s research interests span the areas of toxicokinetics, applied pharmacokinetics and method development. He has over 100 publications, abstracts and book articles to his credit.


Treasurer
Dr. Loralie Langman
 Loralie Langman, Ph.D. got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta and University of Alberta Hospital. After working for a few years as a laboratory technologist, she then went back to school and completed her Ph.D. in Medicine – Laboratory Medicine and Pathology at the University of Alberta. She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics. Prior to coming to Mayo Clinic Rochester, she was in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, and Toxicological Chemistry). She is also a Diplomat with the American Board of Forensic Toxicology. Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists; the American Academy of Forensic Sciences; the National Academy of Clinical Biochemistry; the American Association for Clinical Chemistry; the Canadian Society of Clinical Chemists; the International Association of Therapeutic Drug Monitoring and Clinical Toxicology; and The International Association of Forensic Toxicologists. Currently, Dr. Langman is Director of the Toxicology and Drug Monitoring Laboratory at Mayo Clinic Rochester. She has over 30 publications and over 40 abstracts/presentations at National and International meetings. Her areas of expertise include: toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management; and pharmacogenetics. Her current research interests include metabolism and pharmacogenomics of amphetamine-type stimulants and cocaine; and genotype phenotype relationships of psychoactive medications.

Dr. Loralie J. Langman
Toxicology and Drug Monitoring Laboratory
Mayo Clinic Hilton 210E
200 First Street SW
Rochester MN 55905
USA
langman.loralie@mayo.edu



Directors of Education

Dr. Vanessa Steenkamp

 Vanessa Steenkamp is Professor of Pharmacology at the University of Pretoria, South Africa.  She is a Senior Lecturer and heads the Phytopharmacology Unit.   Prof Steenkamp obtained her PhD in Clinical Chemistry specializing in clinical toxicology at the University of the Witwatersrand.  She is registered with the Health Professional Council of South Africa as well as the South African council for Natural Scientific Professions. Her research focus is the determination of biological activity of traditional herbal remedies in order to identify compounds with pharmacological activity, which can be developed as new agents in treatment of diseases.  Prof Steenkamp is the author and co-author of 56 scientific papers.  She has received numerous awards for her research both nationally and internationally. She is the President of the South African Association of Clinical Biochemists, Vice-President of the Toxicology Society of South Africa, Secretary-General of the South African Association of Basic and Clinical Pharmacology, Treasurer of the Federation of the South African Society of Pathologists.  Internationally, Vanessa serves as steering member of the Committee for Congresses & Conferences on the IFCC and as Director of Education and Committee member of the Clinical Toxicology Committee of the IATDMCT.  She is the National representative for Clinical Chemistry in South Africa to the International Federation of Clinical Chemistry.   She was recently selected first President of the African Federation of Clinical Chemistry. She serves as reviewer for 14 journals as well as research proposals for funding bodies and is on the editorial board of two journals. She has 149 conference contributions and has been the invited speaker on 14 occasions.



Dr. Teun Van Gelder, MD, PhD

 Dr. Teun van Gelder is an internist and clinical pharmacologist in the Department of Hospital Pharmacy at the Erasmus Medical Center in Rotterdam, the Netherlands. He was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University, and was awarded the Young Investigator Award from the American Society for Transplantation for his work during this time. Dr. van Gelder’s current research at the Erasmus Medical Center is focused on clinical pharmacology and therapeutic drug monitoring.

Dr. Teun Van Gelder, MD, PhD
Internist
Erasmus Medical Center
Molewaterplein 40
Rotterdam 3015 GD
The Netherlands
t.vangelder@erasmusmc.nl

Dr. Pierre Wallemacq

 Pierre Wallemacq is Professor at the Université catholique de Louvain, Medical school in Brussels, Belgium. He teaches clinical chemistry, toxicology and clinical pharmacokinetics, and is the vice president of the biomedical sciences school. He is responsible of a research unit (LBCM) in the Medical School and supervises several PhD theses. He is also head of laboratory in the Cliniques universitaires St Luc, Brussels, in charge of the analytical biochemistry platform regrouping activities such as TDM, clinical toxicology, forensic toxicology, but also special chemistry (GC, HPLC, UPLC, LC-MSMS, GC-MS etc…). He started working in the field of TDM since 1982 with his PhD thesis on cyclosporine, and is author or coauthor of more than 110 manuscripts with peer-reviews and several chapters of textbooks. Most of his work was dedicated to immunosuppressive drugs, but he also published works in other clinical chemistry of TDM/TOX areas. Pierre Wallemacq has been elected president of the Royal Belgian Society of Clinical Chemistry (SBCC-BVKC) in 2008, and president of the Belgian and Luxemburg society of Toxicology (BLT) in 2007. He is member of the Editorial Boards of several International Journals such as Therapeutic Drug Monitoring (TDM), Clinical Biochemistry (CLB), Clinical Chemistry and Laboratory Medicine (CCLM). He has been involved as member of the scientific organization committees of several international congresses.

 

Prof. Pierre Wallemacq
Dept. of Clinical Chemistry
University Hospital St. Luc
Av. Hippocrate 10
B-1200 Bruxelles 1200
Belgium

Councillors
Dr. William Clarke, USA

 Dr. Clarke received his Ph.D. in Analytical Chemistry from the University of Nebraska in Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002.  In addition, he received an MBA focused on medical services management from the Carey School of Business at Johns Hopkins in 2007.  Following his post-doctoral fellowship, he has remained at Johns Hopkins, where he is an Assistant Professor in the Department of Pathology, as well as the director of both Point-of-Care Testing and TDM/Toxicology for the hospital.  Dr. Clarke is board certified in Clinical Chemistry by the American Board of Clinical Chemistry, and is a Fellow of the National Academy of Clinical Biochemistry.  His research interests include method development and evaluation for TDM, pharmacogenomics, pharmacoproteomics, and the study of outcomes and medical decision-making in the context of variability in laboratory measurements. 

 

Dr. Clarke has published 30 papers in journals such as Analytical Chemistry, Journal of Chromatography, Clin Chim Acta, and Annals of Surgery, as well as 24 book chapters.  He is a co-editor of the book Contemporary Practice in Clinical Chemistry, and is currently the sole editor for the second edition of that book.  Dr. Clarke was the recipient of the 2004 George Grannis Award from the NACB for excellence in research and publication by a young investigator, and also the 2005 AACC TDM/Toxicology Division Young Investigator Award.

 

Dr. Mercè Brunet (Spain)
Dr. Frank T. Peters (Germany)

 Frank T. Peters was born in Trier, Germany, in 1971, where he also went to elementary school and high school. He started studying pharmacy at the Johann-Wolfgang-Goethe University in Frankfurt/Main, Germany, in 1993 and obtained the licence to practice as a pharmacist in 1998.
Thereafter, he started working as a research assistant and PhD student of Prof. Dr. Dr. h.c. Hans H. Maurer at the Department of Experimental and Clinical Toxicology of the Saarland University in Homburg, Germany, where he finished his PhD thesis in June of 2003. From then to the end of 2008 he worked in the same department as a post-doc and deputy of Prof. Maurer. In June 2009 he finished his habilitation (licence to lecture at the university) in the field of pharmacology and toxicology at the Medical Faculty of the Saarland University. Since 2009 he is the Head of Forensic and Clinical Toxicology at the Institute of Forensic Medicine at the University Hospital in Jena, Germany.
The main research interests of Frank T. Peters are biotechnological synthesis of drug metabolites, enantioselective analysis of amphetamines and amphetamine-like designer drugs, analysis of new designer drugs in blood samples, metabolism of drugs and poisons, determination of sedating drugs in the context of declaration of brain death, and experimental designs and statistical procedures for analytical method validation.
Frank T. Peters is author or co-author of 59 peer-reviewed publications, one book and six book chapters. He is a member of The International Association of Forensic Toxicologists (TIAFT), the German Pharmaceutical Society (DPhG), the Society of Toxicological and Forensic Chemistry (GTFCh), and of the International Association of Therapeutic Drug Monitoring &Clinical Toxicology (IATDMCT). Frank T. Peters is chairman of IATDMCT’s and TIAFT’s Young Scientist Committees.

During the TIAFT meeting in Melbourne in 2003 he received the TIAFT Young Scientist Award for Best Paper Published in 2002 for his publication on “Bioanalytical method validation and its implications for forensic and clinical toxicology – A review.” In 2007, he received the Young Scientist Award of the GTFCh. The IATDMCT Young Investigator Award was presented to him during the IATDMCT meeting in Montreal, 2009 

 

Dr. Benedetta Salustio (Australia)

 Dr Sallustio was awarded her PhD in 1990 from Flinders University in South Australia. She is currently Principal Medical Scientist in the Department of Clinical Pharmacology at The Queen Elizabeth Hospital, and Affiliate Associate Professor in the Discipline of Pharmacology at the University of Adelaide, in South Australia.
Dr Sallustio’s area of research interests include drug metabolism and transport, particularly understanding how inter-individual differences in these processes, either genetic or environmental, impact on drug toxicity and clinical efficacy. She has pursued three main arms of research: i) the role of metabolism in enhancing drug toxicity, particularly intracellular protein and genetic damage; ii) applying an understanding of metabolic pathways and their genetic variability to enhance the clinical use of the anti-anginal agent perhexiline; and iii) applying an understanding of variability in the metabolism and cellular transport of immunosuppressants to improving clinical outcomes in renal transplant recipients. This work has been supported by major competitive funding from the National Heart Foundation, the Anti Cancer Foundation, the National Health and Medical Research Council, and the Juvenile Diabetes Research Foundation, and has resulted in 60 peer-reviewed publications in international journals and 103 presentations at national and international scientific meetings.
Dr Sallustio is a member of a number of national and international scientific societies and currently serves as Convenor of the Adelaide Pharmacology Group, is on the Scientific Advisory Committee of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (since 2007), and is an elected Councillor of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (2009-2011).

A/Prof Bendetta C Sallustio
Department of Clinical Pharmacology
The Queen Elizabeth Hospital, Basil Hetzel Institute
28 Woodville Road
Woodville SA 5011 Australia
benedetta.sallustio@health.sa.gov.au 

 

 

Powered By Dragonfly IT Ltd.